Fasting and fasting-mimicking treatment activate SIRT1/LXRα and alleviate diabetes-induced systemic and microvascular dysfunction

Sandra S. Hammer,Cristiano P. Vieira,Delaney McFarland,Maximilian Sandler,Yan Levitsky,Tim F. Dorweiler,Todd A. Lydic,Bright Asare-Bediako,Yvonne Adu-Agyeiwaah,Micheli S. Sielski,Mariana Dupont,Ana Leda Longhini,Sergio Li Calzi,Dibyendu Chakraborty,Gail M. Seigel,Denis A. Proshlyakov,Maria B. Grant,Julia V. Busik
DOI: https://doi.org/10.1007/s00125-021-05431-5
IF: 8.2
2021-03-26
Diabetologia
Abstract:<span><i>Homo sapiens</i> evolved under conditions of intermittent food availability and prolonged fasting between meals. Periods of fasting are important for recovery from meal-induced oxidative and metabolic stress, and tissue repair. Constant high energy-density food availability in present-day society contributes to the pathogenesis of chronic diseases, including diabetes and its complications, with intermittent fasting (IF) and energy restriction shown to improve metabolic health. We have previously demonstrated that IF prevents the development of diabetic retinopathy in a mouse model of type 2 diabetes (<i>db</i>/<i>db</i>); however the mechanisms of fasting-induced health benefits and fasting-induced risks for individuals with diabetes remain largely unknown. Sirtuin 1 (SIRT1), a nutrient-sensing deacetylase, is downregulated in diabetes. In this study, the effect of SIRT1 stimulation by IF, fasting-mimicking cell culture conditions (FMC) or pharmacological treatment using SRT1720 was evaluated on systemic and retinal metabolism, systemic and retinal inflammation and vascular and bone marrow damage.</span>
endocrinology & metabolism
What problem does this paper attempt to address?